Treating dementia by blood brain barrier opening to increase glymphatic clearance - From mechanisms to therapeutic applications
Description of the granted funding
Alzheimer's disease (AD) currently complicates the lives of 50 million people with deterioration of mental skills and personality. Today AD costs 1 trillion € annually and by 2030 the cost will double. In OPEN-consortium we have detected failures in a brain clearance mechanism that lead to AD. Based on our findings, we have further developed novel tools for detecting the failing brain clearance along with new ways to boost the brain clearance, such that the AD development might be slowed down or even prevented. In the continued plans are that we will further increase the efficiency of the treatment options and expand our research to see how efficient our tools are in detecting and monitoring AD pathology in humans. We aim to develop novel multi-level treatment strategy that incorporates a spectrum of options extending from easy to use non-invasive therapies into more invasive treatments for advanced diseases states that can be tailored to suite patient treatment at individual level.
Show moreStarting year
2021
End year
2023
Granted funding
Role in consortium of the Academy of Finland
Partner
Funder
Research Council of Finland
Funding instrument
Academy programme
Other information
Funding decision number
335723
Fields of science
Biochemistry, cell and molecular biology
Research fields
Solu- ja molekyylibiologia
Identified topics
brain, neuroscience